Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic
Martín-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Hindi, Nadia (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Aguiar Júnior, Samuel (A.C. Camargo Cancer Center. Department of Pelvic Surgery)
Badilla-González, Ronald (Rafael Ángel Calderón Guardia Hospital. Department of medical oncology)
Castro-Oliden, Victor (Instituto Nacional de Enfermedades Neoplásicas (Lima, Perú))
Chacón, Matias (Alexander Fleming Cancer Institute (Buenos Aires, Argentina))
Correa Genoroso, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
De Álava, Enrique (Universidad de Sevilla)
Donati, Davide María (Rizzoli Orthopedic Institute)
Eriksson, Mikael (Skåne University Hospital (Suècia))
Falla-Jimenez, Martin (Instituto Nacional de Enfermedades Neoplásicas (Lima, Perú))
German, Gisela (Hospital Oncológico Provincial (Córdoba, Argentina))
Gobo Silva, Maria Leticia (A.C. Camargo Cancer Center)
Gouin, François (Centre León Bérard)
Gronchi, Alessandro (University of Milan)
Haro-Varas, Juan (Instituto Nacional de Enfermedades Neoplásicas (Lima, Perú))
Jiménez-Brenes, Natalia (San Vicente de Paúl Hospital)
Lopes de Mello, Celso Abdon (A.C. Camargo Cancer Center)
Kasper, Bernd (Mannheim University Medical Cente)
Maki, Robert G (University of Pennsylvania)
Martínez-Delgado, Paula (Instituto de Biomedicina de Sevilla)
Martínez-Said, Hector (Instituto Nacional de Cancerología (Ciutat de Mèxic))
Martinez-Tlahuel, Jorge Luis (Instituto Nacional de Cancerología (Mèxic))
Morales-Pérez, Jose Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Muñoz-Casares, Francisco Cristobal (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Nakagawa, Suely A. (A.C. Camargo Cancer Center)
Ortiz-Cruz, Eduardo Jose (Hospital Universitario La Paz (Madrid))
Palmerini, Emanuela (Rizzoli Orthopedic Institute)
Patel, Shreyaskumar (University of Texas MD Anderson Cancer Center (Houston))
Moura, David S. (Insituto de Biomedicina de Sevilla)
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Sunyach, Marie Pierre (Centre León Bérard)
Valverde, Claudia M. (Hospital Universitari Vall d'Hebron)
Waisberg, Federico (Alexander Fleming Cancer Institute (Buenos Aires, Argentina))
Blay, Jean-Yves (Centre León Bérard)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Background: The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. Material and Methods: A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The consensus level for each recommendation was classified as "strongly recommended" (SR) if more than 90% of experts agreed, "recommended" (R) if 75%-90% of experts agreed and "no consensus" (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization. Results: There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively). Conclusion: The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak. Implications for Practice: The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.
Ajuts:	European Commission. Horizon 2020 825806
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; Sarcoma ; Guidelines ; Patient care ; Multidisciplinary
Publicat a:	The Oncologist, Vol. 25 Núm. 10 (october 2020) , p. e1562-e1573, ISSN 1549-490X

DOI: 10.1634/theoncologist.2020-0516
PMID: 32888360

12 p, 577.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats